Andrew Engdahl, the Head of Sales at the post-click automation platform Instapage, has been officially nominated as a candidate for the Blood Cancer United Visionaries of the Year campaign. This prestigious philanthropic competition recognizes business and community leaders who leverage their professional networks and personal platforms to generate significant funding for blood cancer research and patient support. The nomination marks a significant milestone for Engdahl, who transitioned from a life-threatening medical crisis in 2022 to a leadership role within one of the marketing technology industry’s most prominent firms.
The Visionaries of the Year campaign is a highly competitive, multi-week initiative where candidates compete to raise the most funds for blood cancer initiatives. Engdahl’s candidacy is not merely a corporate philanthropic gesture but is deeply rooted in his personal history as a survivor of Stage 4 Non-Hodgkin’s Lymphoma. His journey from a critical diagnosis to three years of remission serves as the foundation for his $50,000 fundraising goal, which he launched in conjunction with World Cancer Day.
The 2022 Diagnosis and Medical Chronology
The trajectory of Andrew Engdahl’s life shifted abruptly in the summer of 2022. At the time, Engdahl was a high-performing member of the Instapage sales team, navigating the high-pressure environment of Silicon Valley SaaS (Software as a Service) sales. What initially appeared to be routine physical discomfort—characterized by muscle tension and localized pain—quickly escalated into a systemic health crisis.
Upon seeking medical intervention, diagnostic imaging and biopsies revealed the presence of Stage 4 Non-Hodgkin’s Lymphoma. In oncology, a Stage 4 diagnosis indicates that the cancer has spread beyond the lymphatic system to distant organs, such as the liver, bone marrow, or, in Engdahl’s case, the skeletal structure. The severity of the progression required immediate and aggressive medical intervention.
The ensuing six months were defined by a rigorous and invasive treatment protocol. Engdahl underwent major spinal surgery to address complications arising from the malignancy, followed by four lumbar punctures—a procedure used to check for the spread of cancer cells in the cerebrospinal fluid or to deliver chemotherapy directly to the central nervous system. His systemic treatment included six intensive rounds of chemotherapy infusions.
In addition to the clinical treatments, Engdahl’s recovery was supported by a dedicated six-month regimen of physical therapy and yoga. This holistic approach was designed to restore the mobility and strength compromised by both the cancer and the surgical interventions. By the conclusion of this period, Engdahl had transitioned from a critical patient status to a survivor in recovery, eventually achieving the three-year remission milestone he celebrates today.
Professional Resilience and Leadership at Instapage
Throughout his medical battle, Engdahl remained a fixture of the Instapage organization. His ability to maintain professional momentum while undergoing aggressive cancer treatment is cited by the company as a testament to his personal resilience. During his tenure, even amidst his recovery, Engdahl was instrumental in securing some of the company’s largest enterprise contracts.
This performance led to his eventual promotion to Head of Sales, where he now oversees the global sales operations for the company. Instapage, which specializes in landing page optimization and conversion rate increases, relies heavily on its sales leadership to drive growth in a crowded MarTech landscape. The company has publicly voiced its support for Engdahl’s campaign, noting that his journey from navigating a life-threatening illness to leading a global team brings a unique perspective of optimism and joy to the corporate culture.
The intersection of his professional success and personal health journey has positioned Engdahl as a "Visionary" candidate. The program specifically looks for individuals who can demonstrate "resilience in the face of adversity" and use their business acumen to solve complex social problems, such as the funding gap in rare cancer research.
Statistical Context of Blood Cancer and Non-Hodgkin’s Lymphoma
Engdahl’s campaign comes at a critical time for blood cancer advocacy. According to data from the American Cancer Society and the Leukemia & Lymphoma Society (LLS), an estimated 1.6 million people in the United States are currently living with or are in remission from a blood cancer. Non-Hodgkin’s Lymphoma (NHL) stands as one of the most common cancers in the U.S., accounting for about 4% of all cancer diagnoses.
The survival rates for NHL have improved significantly over the last several decades due to advancements in immunotherapy and targeted treatments funded by initiatives like Visionaries of the Year. While the five-year relative survival rate for NHL is approximately 74%, that figure fluctuates significantly based on the stage of the cancer and the specific subtype. A Stage 4 diagnosis, such as Engdahl’s, typically presents a more challenging prognosis, making his full recovery and current health status a significant outcome that underscores the importance of early detection and advanced treatment protocols.
Research indicates that the financial burden of these treatments is substantial. A single course of modern chemotherapy and associated surgeries can cost hundreds of thousands of dollars. Fundraising efforts like Engdahl’s $50,000 campaign are directed toward three primary pillars:
- Research: Funding the next generation of blood cancer treatments, including CAR-T cell therapy and monoclonal antibodies.
- Patient Support: Providing financial assistance and educational resources to families navigating the complexities of a diagnosis.
- Policy and Advocacy: Working at the state and federal levels to ensure patients have access to affordable, high-quality care.
The Visionaries of the Year Campaign Structure
The Visionaries of the Year campaign, organized by Blood Cancer United (often associated with the LLS regional chapters), is a 10-week philanthropic competition. Candidates are selected based on their leadership standing within their respective communities. Each candidate forms a team of supporters to help reach their fundraising targets.
Engdahl’s campaign is characterized by its "Pay It Forward" philosophy. In his official campaign statement, he emphasized a sense of duty toward the medical professionals and support systems that facilitated his recovery. "I feel that I owe it to my physicians, my friends, family, and teammates, and all those affected by the scourge of blood cancer to pay it forward and make a difference while I still have the strength and ability to do so," Engdahl stated.
The campaign utilizes digital platforms to solicit donations and spread awareness. Supporters can track progress through a dedicated campaign page, where Engdahl shares updates on his journey and the impact of the funds raised. The competition concludes with a grand finale gala, where the top fundraisers are recognized, and the total impact of the cohort is announced.
Corporate and Community Implications
The support from Instapage highlights a growing trend in corporate social responsibility (CSR), where companies move beyond generic charitable giving to support the specific causes championed by their leadership. By amplifying Engdahl’s story, Instapage is not only supporting a key executive but also fostering a culture that acknowledges the "human element" of the workforce.
Industry analysts suggest that when high-level executives share personal vulnerabilities—such as a cancer diagnosis—it can have a profound impact on employee morale and retention. It humanizes the leadership team and reinforces a supportive work environment. For Instapage, Engdahl’s campaign serves as an example of how personal adversity can be transformed into a platform for broader social benefit.
Furthermore, the campaign highlights the role of "survivor-advocates" in the nonprofit sector. Individuals like Engdahl, who have navigated the healthcare system as patients, are often the most effective at identifying the gaps in care and research. Their stories provide a face to the statistics, making the need for funding more tangible to potential donors who may not have a direct connection to blood cancer.
Broader Impact on Cancer Research
The funds raised through Engdahl’s $50,000 goal contribute to a larger pool of capital that has historically changed the landscape of oncology. Since its inception, the LLS and its associated "Visionaries" programs have invested more than $1.7 billion in cutting-edge research. This investment has played a role in nearly every advancement in blood cancer treatment, including the development of drugs that are now being used to treat other forms of cancer and chronic diseases.
As Engdahl moves forward with his campaign, the focus remains on the "second chance at life" he was afforded. His transition from a patient receiving six chemotherapy infusions to a Head of Sales leading a global team is a narrative of recovery that the Visionaries of the Year program seeks to highlight. The campaign will continue through the spring, with the final results expected to contribute to the national effort to eradicate blood cancers and improve the quality of life for survivors.
For those interested in contributing to the effort or learning more about the medical milestones achieved through these funds, Andrew Engdahl’s campaign page remains active, serving as a hub for both donations and educational content regarding the fight against Non-Hodgkin’s Lymphoma.
